The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Palisade Bio Inc (NASDAQ: PALI) was $1.72 for the day, down -4.97% from the previous closing price of $1.81. In other words, the price has decreased by -$4.97 from its previous closing price. On the day, 6.75 million shares were traded. PALI stock price reached its highest trading level at $1.83 during the session, while it also had its lowest trading level at $1.65.
Ratios:
Our analysis of PALI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 1.78. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PALI now has a Market Capitalization of 256629536 and an Enterprise Value of 251271520.
Stock Price History:
The Beta on a monthly basis for PALI is 1.48, which has changed by 0.034285665 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, PALI has reached a high of $2.59, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is -10.05%, while the 200-Day Moving Average is calculated to be 61.77%.
Shares Statistics:
PALI traded an average of 8.69M shares per day over the past three months and 5956470 shares per day over the past ten days. A total of 149.00M shares are outstanding, with a floating share count of 139.74M. Insiders hold about 6.22% of the company’s shares, while institutions hold 38.39% stake in the company. Shares short for PALI as of 1764288000 were 13976371 with a Short Ratio of 1.61, compared to 1761868800 on 7594147. Therefore, it implies a Short% of Shares Outstanding of 13976371 and a Short% of Float of 9.379999999999999.
Earnings Estimates
The firm’s stock currently is rated by 3.0 analysts. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.18 and -$1.48 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.19, with 3.0 analysts recommending between -$0.09 and -$0.33.
